What is the fair value of I Mab (NASDAQ-NBP) stock?

The current fair value estimate for I Mab (NASDAQ-NBP) is $2.47. This implies an estimated upside of 55.5% versus the current market price.

Is I Mab (NASDAQ-NBP) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 55.5% versus the current market price.

What is the analyst price target for NASDAQ-NBP stock?

The available analyst price target for I Mab (NASDAQ-NBP) is $9. The analyst target implies estimated upside of 466.0%.

How is the financial health of I Mab?

The current financial health read for I Mab (NASDAQ-NBP) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is I Mab's next earnings date?

The next earnings date currently listed for I Mab (NASDAQ-NBP) is November 12, 2026.

Does I Mab (NASDAQ-NBP) pay dividends?

The latest available data indicates no current dividend yield for I Mab (NASDAQ-NBP).

What is the market capitalization of I Mab?

The current market capitalization listed for I Mab is 184.4 M.

What is the enterprise value of I Mab?

The current enterprise value listed for I Mab is 369.737 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for I Mab?

The ticker symbol for I Mab is NASDAQ-NBP, and the stock is listed on NASDAQ.

Where is I Mab (NASDAQ-NBP) listed?

I Mab (NASDAQ-NBP) is listed on NASDAQ.

What is the debt-to-total-capital ratio for I Mab?

The current debt-to-total-capital ratio listed for I Mab is 2.3%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for I Mab?

The free float listed for I Mab is 55.6%. Free float helps investors understand how much of the share base is available for public trading.

I Mab (NBP) Fair Value & Stock Analysis

I Mab (NBP)

I Mab (NBP) is a NASDAQ-listed depositary receipt representing common stock of NovaBridge Biosciences, a biotechnology company focused on immuno-oncology research for cancer treatment in the United States. The company is advancing givastomig, a bispecific antibody in a Phase 1b trial for gastric cancer, as well as uliledlimab, a CD73 neutralizing antibody, and ragistomig, a bispecific antibody in a Phase 1 trial for solid tumors. NovaBridge Biosciences also has a strategic licensing agreement with Ferring International Center SA covering FE301, an interleukin-6 inhibitor, and collaboration arrangements with Bristol Myers Squibb, ABL Bio, and TJ Bio tied to its development programs. Founded in 2014 and headquartered in Rockville, Maryland, the company was previously known as I-Mab before adopting the NovaBridge Biosciences name in October 2025.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-NBP	$2.47	55.5% Upside	Bargain	$9	466.0% Upside	Bargain	Fair	0.0%	November 12, 2026	0.9x	184.4 M	369.737 K	2.3%	55.6%	-5.5	39.7%